Tzianabos Arthur
- SEC CIK
- 0001586226
In the past year, 1 open-market sale filing worth $174.2K and no purchases.
Current role at each company
- QTTB Q32 Bio Inc.Directoras of Jul 21, 2026
- STOK Stoke Therapeutics, Inc.Directoras of Jun 5, 2026
- AKUS Akouos, Inc.Directoras of Dec 2, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $174.2K
- 1 filing
- Net
- −$174.2K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Tzianabos Arthur as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
STOK Stoke Therapeutics, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 (view filing) | Mar 10 | 2 days | Tzianabos ArthurInterim Executive Chair | SSale | −4.36K | $40.00 | −$174.2K | −12.2%31.3K after | 10b5-1 |
QTTB Q32 Bio Inc.
Director4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 14, 2024 (view filing) | Mar 25 | 142 daysLate | Tzianabos ArthurDirector | SSale | −265 | $24.20 | −$6.41K | −3.2%7.98K after | |
| Feb 15, 2024 (view filing) | Jan 9 | 37 daysLate | Tzianabos ArthurDirector | SSale | −13.0K | $0.57 | −$7.43K | −9.2%128.8K after | 10b5-1 |
| Jan 11, 2023 (view filing) | Jan 9 | 2 days | Tzianabos ArthurDirector | SSale | −10.6K | $1.39 | −$14.8K | −8.9%108.4K after | |
| Jan 12, 2022 (view filing) | Jan 5 | 7 daysLate | Tzianabos ArthurPresident & CEO | SSale | −5.35K | $3.78 | −$20.2K | −5.9%86.0K after |